These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22592438)

  • 1. Lanthanum carbonate and peritoneal catheter dysfunction.
    Rodríguez-Palomares JR; de Arriba G; Gómez L; Pérez K; Basterrechea M; Hernández B; Tallón S
    Nefrologia; 2012 May; 32(3):415-6. PubMed ID: 22592438
    [No Abstract]   [Full Text] [Related]  

  • 2. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
    Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
    [No Abstract]   [Full Text] [Related]  

  • 3. [Radiographic characteristics of lanthanum carbonate absorption].
    Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
    Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intestinal pseudo-occlusion due to lanthanum carbonate].
    Pobes Martínez de Salinas A; Blanco Rodríguez I; Quiñones Ortiz L; Suárez Laurés A
    Nefrologia; 2010; 30(3):376. PubMed ID: 20514115
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral phosphate binders in patients with kidney failure.
    Tonelli M; Pannu N; Manns B
    N Engl J Med; 2010 Apr; 362(14):1312-24. PubMed ID: 20375408
    [No Abstract]   [Full Text] [Related]  

  • 6. [Radiology image of lanthanum carbonate].
    Díez Ojeda B; Medrano Martínez S; Alonso Alvarez MA
    Nefrologia; 2010; 30(2):263-4. PubMed ID: 20393629
    [No Abstract]   [Full Text] [Related]  

  • 7. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
    Hutchison AJ; Gill M; Copley JB; Poole L; Wilson RJ
    BMC Nephrol; 2013 Feb; 14():40. PubMed ID: 23418668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum carbonate: safety data after 10 years.
    Hutchison AJ; Wilson RJ; Garafola S; Copley JB
    Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
    Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
    Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
    Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
    Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD.
    Kawanishi H; Ishida M; Ishizaki M; Takuma Y; Tamura H; Kobayashi S; Tamura T; Ohashi H; Hiramatsu M; Minakuchi J; Hirakata H; Shigematsu T;
    Perit Dial Int; 2008; 28(6):673-5. PubMed ID: 18981401
    [No Abstract]   [Full Text] [Related]  

  • 18. [Advances in blood purification medicine in 2008].
    Shigematsu T; Negi S; Sakaguchi T; Oda H; Ohura M
    Nihon Jinzo Gakkai Shi; 2009; 51(1):27-32. PubMed ID: 19238905
    [No Abstract]   [Full Text] [Related]  

  • 19. Unusual image of lanthanum carbonate in the abdominal radiograph.
    Vila-Navarro S; Gomila-Roy GE; Hemfelt-Minobis A; Khorrami-Minaei S; Ginard-Vicens D
    Rev Esp Enferm Dig; 2012 Jul; 104(7):379-80. PubMed ID: 22849499
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.